IL4 and eosinophilic esophagitis: Statement #26: Dupilumab (anti IL-4/13) is a Health Canada approved biologic for EoE and can be considered for disease (1) refractory to conventional treatments; or (2) those experiencing side effects with conventional therapy; (3) and/or patients with currently approved concurrent severe allergic conditions.